Recent Breakthrough Designations Break New Ground
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Vaccines and gene therapies are added to the list of types of drugs that could garner the expedited development pathway from the U.S. regulatory agency, with Novartis and Celladon being the most recent companies to tout the status.